Search Results - "Sánchez, Luis Manso"

Characterization of plasma circulating small extracellular vesicles in patients with metastatic solid tumors and newly diagnosed brain metastasis by Carretero-González, Alberto, Hergueta-Redondo, Marta, Sánchez-Redondo, Sara, Ximénez-Embún, Pilar, Manso Sánchez, Luis, Gil, Eva Ciruelos, Castellano, Daniel, de Velasco, Guillermo, Peinado, Héctor

“…Nearly 40% of the advanced cancer patients will present brain metastases during the course of their disease, with a 2-year life expectancy of less than 10%…”
Get full text

Experience with eribulin in the treatment of elderly women with metastatic breast cancer: case studies by Garrido, Maria Lomas, Morago, Ana Jaén, Rovira, Pedro Sánchez, Olarte, Paula Espinosa, Sánchez, Cristina Pernaut, Sánchez, Luis Manso

“…Although advancing age can greatly increase the complexities of treating metastatic breast cancer, chronological age alone is insufficient to determine the…”
Get full text

European value-based healthcare benchmarking: moving from theory to practice by García-Lorenzo, Borja, Gorostiza, Ania, Alayo, Itxaso, Castelo Zas, Susana, Cobos Baena, Patricia, Gallego Camiña, Inés, Izaguirre Narbaiza, Begoña, Mallabiabarrena, Gaizka, Ustarroz-Aguirre, Iker, Rigabert, Alina, Balzi, William, Maltoni, Roberta, Massa, Ilaria, Álvarez López, Isabel, Arévalo Lobera, Sara, Esteban, Mónica, Fernández Calleja, Marta, Gómez Mediavilla, Jenifer, Fernández, Manuela, del Oro Hitar, Manuel, Ortega Torres, María del Carmen, Sanz Ferrandez, María Consuelo, Manso Sánchez, Luís, Serrano Balazote, Pablo, Varela Rodríguez, Carolina, Campone, Mario, Le Lann, Sophie, Vercauter, Piet, Tournoy, Kurt, Borges, Marina, Oliveira, Ana Sofía, Soares, Marta, Fullaondo, Ane

“…Abstract Background Value-based healthcare (VBHC) is a conceptual framework to improve the value of healthcare by health, care-process and economic outcomes…”
Get full text

Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer by Graybill, Whitney, Vergote, Ignace, Pothuri, Bhavana, Anttila, Maarit, O'Malley, David, Lorusso, Domenica, Haggerty, Ashley, Fabbro, Michel, Chan, John, Heitz, Florian, Willmott, Lyndsay, Bruchim, Ilan, Zhuo, Ying, Estévez-García, Purificación, Monk, Bradley, Denys, Hannelore, Knudsen, Anja, Tinker, Anna, Sánchez, Luis Manso, Provencher, Diane, Barretina-Ginesta, M. Pilar, Hartman, John, Booth, Donna, González-Martín, Antonio

Get full text

Immunogenicity and clinical activity of tipapkinogen sovacivec (TG4001), an HPV-16 cancer vaccine: A randomized phase 2 study in advanced anogenital cancers by Le Tourneau, Christophe, Rolland, Frederic, Capitain, Olivier, Daste, Amaury, Cassier, Philippe Alexandre, Salas, Sebastien, Manso Sánchez, Luis, Casado Herraez, Antonio, Colon-Otero, Gerardo, Eberst, Lauriane, Jamet, Camille, Lalanne, Ana, Lantz, Olivier, Makhloufi, Hakim, TAVERNARO, Annette, Bendjama, Kaidre, Brandely-Talbot, Maud, Delord, Jean-Pierre

“…2630 Background: Human papillomavirus 16 (HPV-16) infection is associated with several cancer types with limited treatment options in the locally R/M settings…”
Get full text

Health-related quality of life (QoL) in platinum-resistant ovarian cancer patients treated with olaparib and pegylated liposomal doxorubicin (PLD), a multicenter single-arm phase II clinical trial (ROLANDO, GEICO-1601) by Perez-Fidalgo, José Alejandro, Cortés Salgado, Alfonso, García, Yolanda, Iglesias, María, Bohn Sarmiento, Uriel, Calvo García, Elisa, Manso Sánchez, Luis, Santaballa, Ana, Oaknin, Ana, Redondo, Andrés, Rubio, María Jesus, González-Martín, Antonio

“…Abstract only 5549 Background: The prognosis for patients with platinum-resistant/refractory ovarian cancer (PROC) is poor, and the aim of treatment is focused…”
Get full text

Medical treatment of advanced colorectal carcinoma by Castro, Cristina Grávalos, Largo, Antonio Jimeno, Sánchez, Luis Manso, Muñoz, M Luz Amador

Get full text

Abstract CT045: A randomized phase II trial of TG4001 plus avelumab versus avelumab alone in recurrent/metastatic (R/M) human papilloma virus (HPV)-16 positive anogenital cancers by Tourneau, Christophe Le, Rolland, Frédéric, Daste, Amaury, Cassier, Philippe, Salas, Sébastien, Sánchez, Luis Manso, Colon-Otero, Gerardo, Eberst, Lauriane, Lantz, Olivier, Lalanne, Ana, Tavernaro, Annette, Makhloufi, Hakim, Bendjama, Kaïdre, Brandely, Maud, Delord, Jean-Pierre

“…Background: Immune checkpoint inhibitors targeting the PD1/PD-L1 axis have made a breakthrough in advanced solid tumors, leading to improved overall survival…”
Get full text

Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study by Jhaveri, Komal L, Lim, Elgene, Jeselsohn, Rinath, Ma, Cynthia X, Hamilton, Erika P, Osborne, Cynthia, Bhave, Manali, Kaufman, Peter A, Beck, J Thaddeus, Manso Sanchez, Luis, Parajuli, Ritesh, Wang, Hwei-Chung, Tao, Jessica J, Im, Seock-Ah, Harnden, Kathleen, Yonemori, Kan, Dhakal, Ajay, Neven, Patrick, Aftimos, Philippe, Yves-Pierga, Jean, Lu, Yen-Shen, Larson, Timothy, Jerez, Yolanda, Sideras, Kostandinos, Sohn, Joohyuk, Kim, Sung-Bae, Saura, Cristina, Bardia, Aditya, Sammons, Sarah L, Bacchion, Francesca, Li, Yujia, Yuen, Eunice, Estrem, Shawn T, Rodrik-Outmezguine, Vanessa, Nguyen, Bastien, Ismail-Khan, Roohi, Smyth, Lillian, Beeram, Muralidhar

“…Imlunestrant is a next-generation oral selective estrogen receptor (ER) degrader designed to deliver continuous ER target inhibition, including in mutant…”
Get full text

Disentangling the value equation: a step forward in value-based healthcare by García-Lorenzo, Borja, Alayo, Itxaso, Arrospide, Arantzazu, Gorostiza, Ania, Fullaondo, Ane

“…Abstract Background The value equation of value-based healthcare (VBHC) as a single figure remains ambiguous, closer to a theoretical framework than a useful…”
Get full text

Abstract PD1-06: Open label phase 1b/2 study of ladiratuzumab vedotin in combination with pembrolizumab for first-line treatment of patients with unresectable locally-advanced or metastatic triple-negative breast cancer by Han, Hyo (Heather), Diab, Sami, Alemany, Carlos, Basho, Reva, Brown-Glaberman, Ursa, Meisel, Jane, Pluard, Timothy, Cortes, Javier, Dillon, Patrick, Ettl, Johannes, Kuemmel, Sherko, Sanchez, Luis Manso, Oliveira, Mafalda, O'Shaughnessy, Joyce, Papish, Steven, Sinha, Rajni, Sterrenberg, Danielle, Stringer-Reasor, Erica, Tsai, Michaela, Vazquez, Rafael Villanueva, Wuerstlein, Rachel, Wang, Yinghui, Wang, Zejing, Boni, Valentina

“…Background Ladiratuzumab vedotin (LV) is an investigational anti-LIV-1 antibody-drug conjugate with a protease-cleavable linker to monomethyl auristatin E…”
Get full text

Adjuvant hormonal therapy in perimenopausal patients by Pinto Marín, Álvaro, Ballesteros García, Ana Isabel, Izarzugaza Perón, Yann, Mansó Sánchez, Luis, López-Tarruella Cobo, Sara, Zamora Auñón, Pilar

“…This section considers the treatment options for perimenopausal women with breast cancer. The perimenopause period begins in the so-called stage 2 of…”
Get full text